Takeda Terminates DNL593 Partnership, Denali Regains Full Rights to FTD-GRN Therapy
DNLI sits 97% above its 52-week low of $10.57.
Summary
Denali Therapeutics announced that Takeda has terminated their collaboration agreement for the investigational therapy DNL593 (PTV:PGRN), which targets GRN-related Frontotemporal Dementia (FTD-GRN). Denali has regained full rights to the program and will continue its development independently. This news follows Denali's recent accelerated FDA approval for AVLAYAH™ and a significant $200 million royalty funding agreement, providing a strong financial backdrop. While the termination shifts the full development costs and risks to Denali, the company stated Takeda's decision was due to "strategic considerations" and not related to DNL593's efficacy or safety data, mitigating immediate concerns about the drug's potential. Denali remains confident in the asset and expects Phase 1/2 trial results by the end of 2026. Investors will now watch for Denali's independent progress with DNL593 and the upcoming trial data.
At the time of this announcement, DNLI was trading at $20.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.3B. The 52-week trading range was $10.57 to $23.77. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.